Phase II Trials Of Aplidin Begin In Hematological Cancers

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

PharmaMar announced that its marine derived antitumor agent, Aplidin, has commenced phase II clinical trials in hematological malignancies, including studies in multiple myeloma (MM), non- Hodgkin lymphoma (NHL) (both aggressive and indolent), and adult acute lymphoblastic leukemia (ALL).